Malignant Syndrome in a Patient with Parkinson's Disease
Malignant syndrome during the course of Parkinson’s disease usually occurs because of withdrawal or dose reduction of anti-Parkinsonian drugs, especially levodopa and may be fatal. Fever, rigidity, autonomic disfunction, elevated creatinin kinase level and confusion are the major clinical findings....
Main Authors: | Nesrin Helvacı Yılmaz, Gökçen Duymaz, Mehmet Akif Yaşar |
---|---|
Format: | Article |
Language: | English |
Published: |
Galenos Yayinevi
2012-09-01
|
Series: | Türk Nöroloji Dergisi |
Subjects: | |
Online Access: | http://www.tjn.org.tr/jvi.aspx?pdir=tjn&plng=eng&un=TJN-39358 |
Similar Items
-
Investigation of <i>PRKN</i> Mutations in Levodopa-Induced Dyskinesia in Parkinson’s Disease Treatment
by: Ana Gabrielle Bispo, et al.
Published: (2023-08-01) -
Amantadine and the Risk of Dyskinesia in Patients with Early Parkinson’s Disease: An Open-Label, Pragmatic Trial
by: Aryun Kim, et al.
Published: (2018-05-01) -
Investigation of the Association of Homocysteine and MTHFR Polymorphisms and Treatment Options in Parkinson’s Disease in Central Anatolian Region*
by: Ramazan Emre, et al.
Published: (2015-12-01) -
Effects of different levodopa doses on blood pressure in older patients with early and middle stages of Parkinson's disease
by: Dan Su, et al.
Published: (2023-07-01) -
Cryptococcal meningitis - a silent culprit behind delirium in a patient with Parkinson’s disease, on levodopa, presenting with urinary tract infection
by: Robin Manappallil
Published: (2016-06-01)